Literature DB >> 23107560

GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system.

Markus T Rojewski1, Natalie Fekete, Stefano Baila, Kim Nguyen, Daniel Fürst, Delbert Antwiler, Julia Dausend, Ludwika Kreja, Anita Ignatius, Luc Sensebé, Hubert Schrezenmeier.   

Abstract

The estimated frequency of MSCs in BM is about 0.001-0.01% of total nucleated cells. Most commonly, one applied therapeutic cell dose is about 1-5 million MSCs/kg body weight, necessitating a reliable, fast, and safe expansion system. The limited availability of MSCs demands for an extensive ex vivo amplification step to accumulate sufficient cell numbers. Human platelet lysate (PL) has proven to be a safe and feasible alternative to animal-derived serum as supplement for MSC cultivation. We have investigated the functionally closed automated cell culture hollow fiber bioreactor Quantum cell expansion system as an alternative novel tool to conventional tissue flasks for efficient clinical-scale MSC isolation and expansion from bone marrow using PL. Cells expanded in the Quantum system fulfilled MSC criteria as shown by flow cytometry and adipogenic, chondrogenic, and osteogenic differentiation capacity. Cell surface expression of a variety of chemokine receptors, adhesion molecules, and additional MSC markers was monitored for several passages by flow cytometry. The levels of critical media components like glucose and lactate were analyzed. PDGF-AA, PDGF-AB/BB, bFGF, TGF-β1, sICAM-1, sVCAM-1, RANTES, GRO, VEGF, sCD40L, and IL-6 were assessed using a LUMINEX platform. Originally optimized for the use of fetal calf serum (FCS) as supplement and fibronectin as coating reagent, we succeeded to obtain an average of more than 100×10(6) of MSCs from as little as 18.8-28.6 ml of BM aspirate using PL. We obtained similar yields of MSCs/µl BM in the FCS-containing and the xenogen-free expansion system. The Quantum system reliably produces a cellular therapeutic dose in a functionally closed system that requires minimal manipulation. Both isolation and expansion are possible using FCS or PL as supplement. Coating of the hollow fibers of the bioreactor is mandatory when loading MSCs. Fibronectin, PL, and human plasma may serve as coating reagents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107560     DOI: 10.3727/096368912X657990

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  37 in total

1.  Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

Authors:  Mark Jones; Marileila Varella-Garcia; Margaret Skokan; Steven Bryce; Jeffrey Schowinsky; Rebecca Peters; Boah Vang; Michelle Brecheisen; Thomas Startz; Nathan Frank; Brian Nankervis
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

Review 2.  Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures.

Authors:  Karen Bieback
Journal:  Transfus Med Hemother       Date:  2013-08-26       Impact factor: 3.747

Review 3.  Biological functions of mesenchymal stem cells and clinical implications.

Authors:  Abderrahim Naji; Masamitsu Eitoku; Benoit Favier; Frédéric Deschaseaux; Nathalie Rouas-Freiss; Narufumi Suganuma
Journal:  Cell Mol Life Sci       Date:  2019-05-04       Impact factor: 9.261

4.  Soluble matrix protein is a potent modulator of mesenchymal stem cell performance.

Authors:  Giselle C Yeo; Anthony S Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-18       Impact factor: 11.205

5.  GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use.

Authors:  Mandana Haack-Sørensen; Ellen Mønsted Johansen; Lisbeth Drozd Højgaard; Jens Kastrup; Annette Ekblond
Journal:  Stem Cells Int       Date:  2022-06-20       Impact factor: 5.131

6.  Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System.

Authors:  Patrick J Hanley; Zhuyong Mei; April G Durett; Maria da Graca Cabreira-Hansen; Marie da Graca Cabreira-Harrison; Mariola Klis; Wei Li; Yali Zhao; Bing Yang; Kaushik Parsha; Osman Mir; Farhaan Vahidy; Debra Bloom; R Brent Rice; Peiman Hematti; Sean I Savitz; Adrian P Gee
Journal:  Cytotherapy       Date:  2014-04-13       Impact factor: 5.414

7.  Validation of Microbiological Testing of Cellular Medicinal Products Containing Antibiotics.

Authors:  Ramin Lotfi; Markus Thomas Rojewski; Philip H Zeplin; Wolfgang Funk; Oliver Pullig; Ulrich Nöth; Hubert Schrezenmeier
Journal:  Transfus Med Hemother       Date:  2019-07-02       Impact factor: 3.747

8.  Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.

Authors:  Helene Häberle; Harry Magunia; Peter Lang; Henning Gloeckner; Andreas Körner; Michael Koeppen; Tamam Backchoul; Nisar Malek; Rupert Handgretinger; Peter Rosenberger; Valbona Mirakaj
Journal:  J Intensive Care Med       Date:  2021-03-05       Impact factor: 3.510

9.  Microcarrier Screening and Evaluation for Dynamic Expansion of Human Periosteum-Derived Progenitor Cells in a Xenogeneic Free Medium.

Authors:  Kathleen Van Beylen; Ioannis Papantoniou; Jean-Marie Aerts
Journal:  Front Bioeng Biotechnol       Date:  2021-05-24

Review 10.  Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review.

Authors:  Luc Sensebé; Mélanie Gadelorge; Sandrine Fleury-Cappellesso
Journal:  Stem Cell Res Ther       Date:  2013-06-07       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.